Dynasty Wealth Management LLC Trims Stake in Astrazeneca Plc $AZN

Dynasty Wealth Management LLC trimmed its stake in Astrazeneca Plc (NYSE:AZN) by 44.1% in the 4th quarter, HoldingsChannel reports. The firm owned 23,782 shares of the company’s stock after selling 18,791 shares during the period. Dynasty Wealth Management LLC’s holdings in Astrazeneca were worth $4,373,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Bank of America Corp DE increased its stake in shares of Astrazeneca by 4.7% in the 3rd quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock worth $2,503,614,000 after purchasing an additional 1,461,786 shares in the last quarter. Fisher Asset Management LLC boosted its holdings in Astrazeneca by 2.1% in the 4th quarter. Fisher Asset Management LLC now owns 21,601,433 shares of the company’s stock worth $3,791,051,000 after buying an additional 438,709 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Astrazeneca by 9.4% in the 3rd quarter. Dimensional Fund Advisors LP now owns 6,805,896 shares of the company’s stock worth $521,517,000 after buying an additional 582,183 shares during the period. Holocene Advisors LP boosted its holdings in Astrazeneca by 41.8% in the 3rd quarter. Holocene Advisors LP now owns 6,129,194 shares of the company’s stock worth $470,232,000 after buying an additional 1,807,565 shares during the period. Finally, Ameriprise Financial Inc. boosted its holdings in Astrazeneca by 13.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 5,707,561 shares of the company’s stock worth $438,342,000 after buying an additional 660,569 shares during the period. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Astrazeneca Trading Down 1.3%

Shares of Astrazeneca stock opened at $177.34 on Wednesday. The firm has a market cap of $275.04 billion, a price-to-earnings ratio of 26.63, a PEG ratio of 1.43 and a beta of 0.25. The business has a 50-day moving average price of $191.20 and a 200-day moving average price of $184.28. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. Astrazeneca Plc has a twelve month low of $137.23 and a twelve month high of $212.71.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. The firm had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. Equities research analysts anticipate that Astrazeneca Plc will post 10.26 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on AZN shares. UBS Group reaffirmed a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a report on Thursday, May 21st. DZ Bank raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a report on Monday. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Twelve equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $205.33.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.